PTC/SB/08a (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT			Complete if Known		
			Application Number	Not Yet Assigned	
			Filing Date	April 12, 2004	
SIAIEMENI	DIAP	PLICANI	First Named Inventor	Tsuyoshi YAMAUCHI	
			Group Art Unit		
(use as mar	y sheets as ne	ecessary)	Examiner Name		
Sheet 1	of	2	Attorney Docket Number	YAMAUCHI=3B	

			U.S. PA	TENT DOCUMENTS	
xaminer nitials*	Cite No. ¹	Document Number Number-Kind Code ^{2 (Victoria)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
BB	AA	US-3,334,118	08-01-1967	SCHAAF, et al.	
1	AB	US-4,719,204	01-12-1988	DELUCA, et al.	
7	AL	US-4,689,180	08-25-1987	DELUCA, et al.	
T	AD	US-4,502,991	03-05-1985	DELUCA, et al.	
	AE	US-4,297,289	10-1981	DELUCA, et al.	
1	AT	US-4,307,025	12-1981	DELUCA, et al.	
	16	US-5,532,229	7-1996	VIETH	
BB		US-5,902,806	5-1999	IKEDA, et al.	
		us-			1
		US-			

			FOREIG	ON PATENT DO	CUMENTS		
Exan Initia		Cite No.1	Foreign Patent Number Country Code ³ Number ⁴ Kind Code ⁸ (<i>if known</i>)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	τ°
E	B	AT	JP 51-15609 A	2-07-1976	EISAI CO LTD		Abs.
	r	AJ	EP0 298757	01-11-1989			
		AK	PCT 9405630	03-17-1994			
		AL	EP 0503630	09-16-1992			
	Π	m	EP 0184206	06-11-1986			
		AN	EP 0671411	09-13-1995			
	П	AD	EP 0184206	11-1986	MIYAMOTO, et al.		
		AP	WO 9412522	06-09-1994	KUBODERA		
3	3	9P	JP 08034769	02-06-1996	CHUGAI PHARMACEUTICAL CO. LTD.		
_							

Examiner Signature	Padio	Date Considered	1/11	100	
			1		

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \(^1\) Applicant's unique citation designation number (optional). \(^2\) See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. \(^3\) Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). \(^5\)For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \(^3\) Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. \(^3\) Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

	Substitute for form 1449A/P	ubstitute for form 1449A/PTO			Complete If Known			
	INFORMATIO		CLOSURE	Application Number	Not Yet Assigned			
	STATEMENT			Filing Date	April 12, 2004			
	SIAIEMENI	DIAP	PLICANI	First Named Inventor	Tsuyoshi YAMAUCHI			
				Group Art Unit				
	(use as man	y sheets as n	ecessary)	Examiner Name				
_	Sheet 2	of	2	Attorney Docket Number	YAMAUCHI=3B			

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examine Initials*	r Cite No.1	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²
B	AP	WAHYUNI, W, and K. Jinno, "Separation of Fat-Soluble Vitamins with Polymer-Coated Silica-Based Octadecyl Bonded Phase in Reversed-Phase Liquid Chromatography", Journal of High Resolution Chromatography & Chromatography Communications. (1987). 10(8):464-465.	
Ì	AS	MIYAMOTO, et al., "Synthetic Studies of Vitamin D Analogues. XIV. Synthesis and Calcium Regulating Activity of Vitamin D Analogues Bearing a Hydroxyalkoxy Group at 2B-Position," CHEM. PHARM. BULL., 41(6):1111-1113 (1993).	
	AT	POSNER, et al., "Sterecontrolled Total Synthesis of Calcitriol Derivatives: 1,25-Dihydroxy-2-(4-hydroxybuty) vitamin D Analogs of an Osteoporosis Drug," J. ORG. CHEM. 59:7855-7861 (1994).	
	au	BARNER, et al., "87. Zur Konfiguration des Vitamin-D-Metabiliten 25,26-Dihydroxycholecaciferol: Synthese von (25S,26)-und (25R-26)-Dihydroxycholecalciferol," HELVETICA. CHIMICA. ACTA. 64:915-938 (1981).	
	AV	XP-002102280, Chemical Abstracts, 124:1300 * Jade reeded	
		XP-002102281, Derwent Publication Ltd., (1995)	
	AX	Chemical Abstracts 124(7):225 (1996), 124:77-3/1p	
B	M	Chemical Abstracts, Vol. 124, No. 7, 77313, 1996.	
		·	

Examiner Signature Police	Date Considered	1/11	106
		1-1	/

^{*} EXAMINER: Initial if reference considered, whather or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.